日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile.

TUB-040 是一种均质亲水性 NaPi2b 靶向 ADC,其稳定连接了依沙替康,具有持久的抗肿瘤活性和良好的耐受性安全性。

Vogl Annette M, Schmitt Saskia, Mai Isabelle, Machui Paul, Herterich Sarah, Leonardi Natascia, Cyprys Philipp, Hauswald Danila, Ochtrop Philipp, Kozlowska Izabela, Kitowski Annabel, Gerlach Marcus, Waldmann Florian, Marcq Olivier, Trail Pamela A, Schumacher Dominik, Fingerle-Rowson Günter R, Hock Björn, Kasper Marc-André, Helma Jonas

Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation

壁细胞衍生的趋化因子为血管巨噬细胞提供了一个保护性微环境,从而保护血管并限制慢性炎症。

Kami Pekayvaz ,Christoph Gold ,Parandis Hoseinpour ,Anouk Engel ,Alejandro Martinez-Navarro ,Luke Eivers ,Raffaele Coletti ,Markus Joppich ,Flávio Dionísio ,Rainer Kaiser ,Lukas Tomas ,Aleksandar Janjic ,Maximilian Knott ,Fitsumbirhan Mehari ,Vivien Polewka ,Megan Kirschner ,Annegret Boda ,Leo Nicolai ,Heiko Schulz ,Anna Titova ,Badr Kilani ,Michael Lorenz ,Günter Fingerle-Rowson ,Richard Bucala ,Wolfgang Enard ,Ralf Zimmer ,Christian Weber ,Peter Libby ,Christian Schulz ,Steffen Massberg ,Konstantin Stark

Macrophage migration inhibitory factor (MIF) and its homolog D-dopachrome tautomerase (D-DT) are significant promotors of UVB- but not chemically induced non-melanoma skin cancer

巨噬细胞移动抑制因子 (MIF) 及其同源物 D-多巴色素互变异构酶 (D-DT) 是 UVB 诱发的非黑色素瘤皮肤癌的重要促进剂,但不是化学诱发的

Sebastian Huth #, Laura Huth #, Ruth Heise, Yvonne Marquardt, Linda Lopopolo, Marta Piecychna, Peter Boor, Günter Fingerle-Rowson, Aphrodite Kapurniotu, Amir S Yazdi, Richard Bucala, Jürgen Bernhagen, Jens Malte Baron

MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model

在实验性多微生物败血症模型中,MIF而非MIF-2能够募集炎症性巨噬细胞。

Pathricia Veronica Tilstam ,Wibke Schulte ,Thomas Holowka ,Bong-Sung Kim ,Jessica Nouws ,Maor Sauler ,Marta Piecychna ,Georgios Pantouris ,Elias Lolis ,Lin Leng ,Jürgen Bernhagen ,Günter Fingerle-Rowson ,Richard Bucala

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

RE-MIND 研究:在复发或难治性弥漫性大B细胞淋巴瘤中比较他法西他单抗联合来那度胺(L-MIND)与真实世界中来那度胺单药治疗队列

Zinzani, Pier Luigi; Rodgers, Thomas; Marino, Dario; Frezzato, Maurizio; Barbui, Anna Maria; Castellino, Claudia; Meli, Erika; Fowler, Nathan H; Salles, Gilles; Feinberg, Bruce; Kurukulasuriya, Nuwan C; Tillmanns, Sascha; Parche, Stephan; Dey, Debarshi; Fingerle-Rowson, Günter; Ambarkhane, Sumeet; Winderlich, Mark; Nowakowski, Grzegorz S

Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study

弥漫性大B细胞淋巴瘤体细胞突变的预后影响及其与细胞起源的关系:来自III期GOYA研究的数据

Bolen, Christopher R; Klanova, Magdalena; Trneny, Marek; Sehn, Laurie H; He, Jie; Tong, Jing; Paulson, Joseph N; Kim, Eugene; Vitolo, Umberto; Di Rocco, Alice; Fingerle-Rowson, Günter; Nielsen, Tina; Lenz, Georg; Oestergaard, Mikkel Z

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

接受苯丁酸氮芥联合奥妥珠单抗或利妥昔单抗治疗的合并症慢性淋巴细胞白血病患者中微小残留病灶的预后价值

Langerak, Anton W; Ritgen, Matthias; Goede, Valentin; Robrecht, Sandra; Bahlo, Jasmin; Fischer, Kirsten; Steurer, Michael; Trněný, Marek; Mulligan, Stephen P; Mey, Ulrich J M; Trunzer, Kerstin; Fingerle-Rowson, Günter; Humphrey, Kathryn; Stilgenbauer, Stephan; Böttcher, Sebastian; Brüggemann, Monika; Hallek, Michael; Kneba, Michael; van Dongen, Jacques J M

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

接受奥妥珠单抗或利妥昔单抗免疫化疗的B细胞淋巴瘤患者存在乙型肝炎病毒再激活的风险

Kusumoto, Shigeru; Arcaini, Luca; Hong, Xiaonan; Jin, Jie; Kim, Won Seog; Kwong, Yok Lam; Peters, Marion G; Tanaka, Yasuhito; Zelenetz, Andrew D; Kuriki, Hiroshi; Fingerle-Rowson, Günter; Nielsen, Tina; Ueda, Eisuke; Piper-Lepoutre, Hanna; Sellam, Gila; Tobinai, Kensei

Macrophage migration inhibitory factor promotes renal injury induced by ischemic reperfusion

巨噬细胞移动抑制因子促进缺血再灌注引起的肾脏损伤

Jin H Li, Ying Tang, Jun Lv, Xiao H Wang, Hui Yang, Patrick M K Tang, Xiao R Huang, Zhi J He, Zi J Zhou, Qiu Y Huang, Jörg Klug, Andreas Meinhardt, Günter Fingerle-Rowson, An P Xu, Zhi H Zheng, Hui Yao Lan

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

Obinutuzumab联合CHOP方案对既往未接受治疗的晚期弥漫性大B细胞淋巴瘤有效且安全性良好:II期GATHER研究

Sharman, Jeff P; Forero-Torres, Andres; Costa, Luciano J; Flinn, Ian W; Inhorn, Lowell; Kelly, Kevin; Bessudo, Alberto; Fayad, Luis E; Kaminski, Mark S; Evens, Andrew M; Flowers, Christopher R; Sahin, Deniz; Mundt, Kirsten E; Sandmann, Thomas; Fingerle-Rowson, Günter; Vignal, Charlotte; Mobasher, Mehrdad; Zelenetz, Andrew D